The timing of intravenous antibiotics and clinical outcomes of <i>Mycobacterium abscessus</i> complex lung diseases-Reference-Cited by-同舟云学术

The timing of intravenous antibiotics and clinical outcomes of Mycobacterium abscessus complex lung diseases

Published:2024-02-01 Issue:2 Volume:28 Page:73-80
ISSN:1027-3719
Container-title:The International Journal of Tuberculosis and Lung Disease
language:en
Short-container-title:int j tuberc lung dis

Author:

Pang A-H.¹,Lin S-W.²,Yang J-H.³,Wang P-H.⁴,Pan S-W.⁵,Wei Y-F.⁶,Chen C-Y.⁷,Lee H-S.⁸,Wu T-S.⁹,Chang C-H.¹⁰,Shu C-C.¹¹

Affiliation:

1. Graduate Institute of Clinical Pharmacy, National Taiwan University, Taipei City,

2. Graduate Institute of Clinical Pharmacy, National Taiwan University, Taipei City, Department of Pharmacy, National Taiwan University Cancer Center, and, School of Pharmacy, National Taiwan University, Taipei City,

3. New Taipei Municipal TuCheng Hospital, New Taipei City,

4. Department of Internal Medicine, Far-Eastern Memorial Hospital, New Taipei City, School of Medicine, National Yang Ming Chiao Tung University, Taipei City,

5. Department of Chest Medicine, Taipei Veterans General Hospital, Taipei City,

6. School of Medicine for International Students, College of Medicine, and, Department of Internal Medicine, E-Da Cancer Hospital, I-Shou University, Kaohsiung City,

7. Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin County,

8. Department of Internal Medicine, E-Da Hospital, Kaohsiung City,

9. Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan City, Departments of

10. Medical Research, and

11. Internal Medicine, National Taiwan University Hospital, Taipei City, Department of Internal Medicine, National Taiwan University College of Medicine, Taipei City, Taiwan

Abstract

<sec><title>BACKGROUND</title>The importance of early intravenous (IV) antibiotic use for Mycobacterium abscessus complex lung diseases (MABC-LD) treatment remains unknown.</sec><sec><title>METHODS</title>A retrospective multi-centre observational study was conducted in Taiwan. Patients who were diagnosed with and received treatment for MABC-LD from January 2007 to April 2021 were included. Treatment outcome was defined as modified microbiological cure of MABC-LD.</sec><sec><title>RESULTS</title>Of the 89 enrolled patients, 34 (38.2%) received IV antibiotics as part of the treatment regimen. The median time to IV initiation was 1 day (IQR 1–49); 24 (70.6%) of these patients received IV agents within 4 weeks, defined as early-use. Forty-two (47.2%) patients achieved modified microbiological cure. In the multivariable logistic analysis, early IV antibiotic use was an independent factor associated with modified microbiological cure (aOR 5.32, 95% CI 1.66–17.00), whereas high radiological score (aOR 0.86, 95% CI 0.73–1.00) demonstrated negative association.</sec><sec><title>CONCLUSIONS</title>In the present study, early use of effective IV antibiotic was prescribed in a low percentage (27%) for MABC-LD. By contrast, early IV antibiotic use was correlated with higher microbiological cure than were late or non-use. Future larger and prospective studies are needed to validate the association.</sec>

Publisher

International Union Against Tuberculosis and Lung Disease